Adverse systemic reaction to benznidazole.
Benznidazole, drug of choice for Chagas disease (CD), has been associated with a high incidence of adverse reactions that can become serious, necessitating discontinuation of the drug. We describe the case of a Bolivian patient living in Spain for 9 years, who, following treatment with benznidazole for CD in indeterminate chronic phase, presented with fever, skin lesions, digestive symptoms, general malaise, and laboratory abnormalities. After the discontinuation of benznidazole and, the intake of antihistamines and systemic corticosteroids, the patient presented a complete resolution of the symptoms. Optimization of dose strategies and development of more effective, and better-tolerated drugs is advisable.
Department of Allergy, Hospital Univesitari i Politècnic La Fe, Valencia, España.
María Verónica Pacheco
MV
Coronel
Infectious Diseases Unit, Hospital Univesitari i Politècnic La Fe, Valencia, España.
Laura Oriente
LO
Frutos
Infectious Diseases Unit, Hospital Univesitari i Politècnic La Fe, Valencia, España.
Eva Calabuig
EC
Muñoz
Department of Allergy, Hospital Univesitari i Politècnic La Fe, Valencia, España.
Diana Kury
DK
Valle
Department of Allergy, Hospital Univesitari i Politècnic La Fe, Valencia, España.
Dolores Hernández Fernández de
DH
Rojas
D014355:Chagas Disease / Q000188:drug therapy; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D008875:Middle Aged; D009593:Nitroimidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D014344:Trypanocidal Agents / Q000009:adverse effects* / Q000627:therapeutic use
D009593:Nitroimidazoles; D014344:Trypanocidal Agents; C009999:benzonidazole